Tehran University of Medical Sciences Acta Medica Iranica 0044-6025 57 3 2019 05 13 173 179 EN Alborz Sherafati Department of Cardiology, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran. Maryam Mehrpooya Department of Interventional Cardiology, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran. Roya Sattarzadeh Badkoubeh Department of Advanced Echocardiography, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran. Farnoosh Larti Department of Advanced Echocardiography, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran. Farhad Shahi Department of Hematology and Oncology, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran. Mehrzad Mirzania Department of Hematology and Oncology, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran. Mohsen Esfandbod Department of Hematology and Oncology, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran. Mohammad Saadat Tehran University of Medical Sciences, Tehran Heart Center, Tehran, Iran. Massoud Ghasemi Department of Interventional Cardiology, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran. AND Research Center of Endovascular Intervention, Tehran, Iran. Jeyran Zebardast Department of Electronic Learning in Medical Education, Imam Khomeini Hospital, Tehran University of Medical Sciences, Tehran, Iran. 2018 06 12 2018 12 19 Breast cancer is the most common cancer among the female population, and its prevalence is increasing worldwide. Trastuzumab (Herceptin) therapy improves prognosis in HER2 positive patients, but Heart Failure (HF) is one of its known complications. In this study, we aimed to assess the potential benefits of prophylactic carvedilol therapy in patients receiving Herceptin. Sixty five patients with HER2 positive breast cancer were enrolled in the study. All of the patients received Herceptin. Twenty seven patients also received carvedilol 6.25 mg twice daily, and 38 patients had usual care. Echocardiography was performed at baseline, and after three months in both groups and changes in cardiac function, parameters were compared between two groups. After 3 months, LA volume index (P=0.012), TAPSE (P=0.009), Tei index (P=0.015) and Lateral Longitudinal Strain (P=0.024) were significantly better in patients receiving carvedilol. Carvedilol can be effective in the prevention of systolic and diastolic dysfunction following Herceptin therapy. https://acta.tums.ac.ir/index.php/acta/article/view/7312 https://acta.tums.ac.ir/index.php/acta/article/download/7312/5233